Device Trial Radar · NCT06076499
A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
325
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Jul 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Noctrix Health, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
Summary
As written by the sponsor on the registry.
Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
Conditions
- Restless Legs Syndrome
Interventions
NTX100Device
NTX100 Tonic Motor Activation (TOMAC) System - a non-invasive peripheral nerve stimulation device programmed to deliver active stimulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointTime frame: 1 year
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Mark J Buchfuhrer, MD Office
Downey, California
Sleep Medicine Specialists of California
San Ramon, California
Neurocare, Inc.
Newton, Massachusetts
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.